TABLE 71Mixed-treatment comparison – GDS at 24–28 weeks (mean change from baseline; all measurement populations): results

TechnologyVs placeboProbability most effective
Effect95% CIProbability more effective than placebo
Placebo0.012
Donepezil0.161−0.402 to 0.7200.8660.453
Galantamine
Rivastigmine0.171−0.159 to 0.4860.9410.491
Memantine−0.099−0.662 to 0.4500.1890.043

From: 3, Assessment of clinical effectiveness

Cover of The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model
The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model.
Health Technology Assessment, No. 16.21.
Bond M, Rogers G, Peters J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.